ClinicalTrials.gov
ClinicalTrials.gov Menu

SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00270413
Recruitment Status : Completed
First Posted : December 26, 2005
Last Update Posted : December 9, 2014
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
prof. dr. Hans Wildiers, Universitaire Ziekenhuizen Leuven

Brief Summary:
This study tests the hypothesis that SU11248 can delay tumor progression after tumor mass reduction by taxanes. This is a dual-arm open-label randomized multicenter phase II clinical trial with 2:1 randomization evaluating the efficacy of SU11248 versus nil in patients with metastatic breast cancer after objective response to taxane chemotherapy. Patients randomized to the placebo arm (Arm B) will be offered the opportunity to receive open-label SU011248 treatment upon development of Response Evaluation Criteria in Solid Tumors (RECIST)-defined disease progression.

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Drug: SU11248 Phase 2

Detailed Description:
This study tests the hypothesis that SU11248 can delay tumor progression after tumor mass reduction by taxanes. This is a dual-arm open-label randomized multicenter phase II clinical trial with 2:1 randomization evaluating the efficacy of SU11248 versus nil in patients with metastatic breast cancer after objective response to taxane chemotherapy. Patients randomized to the placebo arm (Arm B) will be offered the opportunity to receive open-label SU011248 treatment upon development of RECIST-defined disease progression

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Belgian Multicenter Phase II Randomized Trial in her2 Negative Metastatic Breast Cancer Evaluating Consolidation Antiangiogenic Therapy With SU11248 After Response to Taxane Chemotherapy Induction
Study Start Date : January 2006
Actual Primary Completion Date : March 2009
Actual Study Completion Date : March 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
sutent
Drug: SU11248
sutent 50 mg daily 4w on 2w off
Other Name: sunitinib
No Intervention: 2



Primary Outcome Measures :
  1. Progression Free Survival (PFS) at 5 months (= proportion of patients alive and free of progression 5 months after starting therapy in the sunitinib arm (control arm = only for descriptive purpose) [ Time Frame: 5 months ]

Secondary Outcome Measures :
  1. To compare other measures of antitumor efficacy in both treatment arms of the study [ Time Frame: 1y ]
  2. To evaluate the safety and tolerability of SU011248 [ Time Frame: 1y ]
  3. To explore the correlations of potential biomarkers with clinical outcomes [ Time Frame: 1y ]
  4. To confirm efficacy of SU11248 in patients of the control group, who receive delayed [ Time Frame: 1y ]
  5. SU11248 treatment at the time progression after taxane chemotherapy. [ Time Frame: 1y ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with metastatic breast cancer, histologically proven
  • Patients received taxane based chemotherapy resulting in PR or CR, and thus had measurable disease at the start of taxane therapy (RECIST)
  • No more than 2 lines (taxanes included) in metastatic setting
  • Patients have received at least 10 weeks of taxane therapy (4 cycles of 3-weekly therapy or 8 weekly administrations) and no more than 20 weeks of treatment (6 cycles of 3-weekly therapy or 16 weekly administrations). 6 cycles of 3-weekly taxanes or 12-16 cycles of weekly taxanes are recommended.
  • Last taxane administration between 3 and 4 weeks for 3 weekly taxane or between 2 and 3 weeks for weekly taxanes
  • Performance status 0 to 1 on the ECOG scale (Appendix A)
  • Age > 18 years
  • Adequate organ function as defined by:
  • Serum aspartate aminotransferase (AST; serum glutamate-oxalate transferase [SGOT]) and serum alanine aminotransferase (ALT; serum glutamate-pyruvate transferase [SGPT]) ≤2.5 x central laboratory upper limit of normal (CL-ULN). If liver function abnormalities are due to underlying malignancy, then AST and ALT may be ≤5 x CL-ULN
  • Prothrombin time (PT) > 50%
  • Serum albumin ≥3.0 g/dL
  • Absolute neutrophil count (ANC) ≥1500/µL
  • Platelets ≥100,000/µL
  • Hemoglobin ≥9.0 g/dL
  • Serum creatinine ≤1.5 x CL-ULN
  • Serum amylase and lipase ≤1.0 x CL-ULN
  • Left ventricular ejection fraction (LVEF) above the lower limit of normal (LLN) as assessed by multigated acquisition (MUGA) scan or echocardiography.
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
  • Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.

Exclusion Criteria:

  • Her2 neu positive tumor with IHC 3+ or FISH+
  • Concurrent hormone therapy (tamoxifen, aromatase inhibitors, other hormone suppressing therapies) with SU11248.
  • Concurrent treatment with hormonal replacement therapy
  • Concurrent treatment with any other anti-cancer therapy. Bisphosphonates are allowed.
  • Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 20 days prior to study entry. Previous trials with antiangiogenic drugs is not allowed.
  • Chronic treatment with steroids unless initiated > 6 months prior to study entry and at low dose (< 20 mg methylprednisolone daily or equivalent)
  • Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma of the cervix uteri.
  • Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic event.
  • Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2, atrial fibrillation of any grade, or prolongation of the QTc interval to >450 msec for males or >470 msec for females.
  • Known human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS)-related illness.
  • Pregnancy or breastfeeding. Patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) within the 7 days prior to enrollment. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.
  • Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00270413


Locations
Belgium
Imelda Bonheiden
Bonheiden, Belgium
AZ st-jan brugge
Brugge, Belgium
AZ VUB
Brussels, Belgium
UCL
Brussels, Belgium
Charleroi
Charleroi, Belgium
UZ Gent
Gent, Belgium, 9000
ZOL
Hasselt, Belgium
UZ Leuven
Leuven, Belgium, 3000
Liege sart-tilman
Liege, Belgium
Namur st-elisabeth
Namur, Belgium
St-Elisabeth Turnhout
Turnhout, Belgium
AZ st-augustinus
Wilrijk, Belgium
Mont-Godinne
Yvoir, Belgium
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
Pfizer
Investigators
Principal Investigator: hans wildiers, MD, PhD UZ Leuven

Responsible Party: prof. dr. Hans Wildiers, adjunct head of clinic, Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier: NCT00270413     History of Changes
Other Study ID Numbers: EudraCT 2005-004587-23
UZL/MBC SUBE0501
First Posted: December 26, 2005    Key Record Dates
Last Update Posted: December 9, 2014
Last Verified: December 2014

Keywords provided by prof. dr. Hans Wildiers, Universitaire Ziekenhuizen Leuven:
breast cancer
metastatic
taxanes
SU11248

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Taxane
Sunitinib
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors